Business
Key takeaways from SRA737 webcast at ASCO
Key takeaways from SRA737 webcast at ASCO.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 9855A Sareum Holdings PLC 03 June 2019 \n\n\n\n\n(AIM: SAR)\n\n\n3 June 2019\n\n\n\n \nThis announcement contains inside information for the purposes of Article 7 of regulation 596/2014\nSareum Holdings PLC\n(\"Sareum\" or the \"Company\")\n \nSareum notes key takeaways from Sierra Oncology webcast discussing positive preliminary results from Phase 1/2 trials with SRA737 presented at ASCO\nSareum Holdings plc (AIM: SAR), the specialist small molecule drug development business, notes that Sierra Oncology (the licence holder for SRA737) held an analyst and investor event today featuring distinguished oncologists Professor Johann de Bono and Dr Rebecca Kristeleit, to discuss clinical findings and possible next steps for SRA737, its oral, highly selective Chk1 inhibitor. Positive preliminary clinical data from two first-in-human Phase 1/2 studies of SRA737, as monotherapy and as SRA737+LDG (low dose gemcitabine), were presented on Saturday 1 June at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Detailed results were issued by press release on 1 June and both press release and the posters are available at www.sierraoncology.com. \n \nThe webcast presentation can be downloaded here.\n \nKey highlights of the webcast were:\n \n· SRA737 is competitively positioned as potentially one of the leading clinical assets targeting the DNA damage repair (DDR) pathway with clinical safety & efficacy of SRA737 +/-LDG supporting standalone development and in combination with both PARP inhibitors (PARPi) and immuno-oncology (IO) therapy such as immune checkpoint blockade\n· The two Phase 1/2 signal-seeking clinical trials were successful in establishing safety and proof-of-concept activity in multiple cancer indications, i.e. identifying genetic contexts that sensitise tumours to SRA737; that LDG potentiates SRA737 activity; and that anti-cancer activity correlated with genetic contexts\n· A very promising signal was observed in anogenital cancer, which represents a tractable opportunity to potentially pursue trials leading to market registration filings given its unmet medical need, particularly in patients for whom initial 1st-line therapy has become ineffective, and substantial potential market oppor...